Inside Rwanda’s Marburg Vaccination Rollout: A Crucial Step to Curb the Outbreak

The Inspirer.

Rwanda is set to launch its first Marburg virus vaccination campaign this Sunday, starting with frontline healthcare workers and individuals already exposed to the virus, marking a significant step in controlling the outbreak.

Health Minister Dr. Sabin Nsanzimana made the announcement during a press briefing on October 6, 2024. The Ministry of Health confirmed the arrival of 700 vaccine doses on October 5, 2024. After swift inspection by various authorities, the vaccination program will target high-risk groups first, including medical personnel treating Marburg patients and individuals who have been in direct contact with infected persons.

“The vaccines arrived [in Rwanda] last night and have already undergone inspection by the relevant bodies, including the National Immunization Program. We are now preparing to start vaccinating those most vulnerable to this virus today,” said Dr. Nsanzimana.

The vaccination drive will prioritize “doctors and healthcare workers treating Marburg patients, as well as those who have had close contact with confirmed cases or deceased victims of the virus.” He added that the effort will also focus on individuals working in high-risk areas, such as intensive care units where critically ill patients are often treated.

Minister Nsanzimana emphasized the importance of vaccinating those in close contact with infected individuals to provide early immunity and halt the spread of the virus.

“When someone is infected, their close contacts are prioritized for vaccination. This is known as ‘ring vaccination,’ aiming to prevent the virus from spreading further. Administering the vaccine within the first few days—or even hours—allows the body to quickly build immunity,” he explained.

The vaccine, known as ‘Sabin’s Vaccine,’ has been previously used in countries like Uganda and Kenya. Dr. Nsanzimana expressed appreciation for the expedited process in Rwanda, noting, “In other countries, the vaccine arrived much later, but here in Rwanda, we managed to get it within just one week of detecting the outbreak. This is faster than usual.”

He also confirmed that the vaccine has passed all trial phases, and the Sabin Vaccine Institute is ready to send additional doses as needed.

As of now, Rwanda has recorded 46 Marburg cases, with 29 individuals still receiving treatment, 12 fatalities, and five recoveries. Minister Nsanzimana also shared promising news, revealing that three more patients may be discharged soon, as their initial tests show signs of recovery.

Patients in Rwanda are currently being treated with two key medications, including Remdesivir, a drug provided by Gilead Sciences Inc. Remdesivir, known for its success in suppressing viral replication during the COVID-19 pandemic, has been adapted to fight the Marburg virus.

“We’ve begun administering Remdesivir, and results are encouraging, depending on how early the treatment is given,” Dr. Nsanzimana reported.

Additionally, a new treatment involving monoclonal antibodies—a first for Marburg treatment—is also being administered, showing promising potential in combating the virus.

As Rwanda embarks on this crucial vaccination campaign, there is hope that this proactive measure will significantly curb the spread of Marburg, bringing the outbreak under control and preventing further loss of life.

theinspirerpublications@gmail.com